SynthesisPloS one2016
A Systematic Review of Diagnostic Biomarkers of COPD Exacerbation.
Synthesis in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Definitions of early COPD and predictors for disease progression: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Breathing insights: Biomarkers as tools for chronic obstructive pulmonary disease assessment - A systematic review.Indian journal of pharmacology · 2026Pooled it
- Extracellular vesicles and chronic obstructive pulmonary disease (COPD): a systematic review.Respiratory research · 2022Pooled it
- Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials.Respiratory research · 2020Pooled it
- Pooled it
- Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial.BMJ open respiratory research · 2019Trial
- Serum 8-OHdG as a Marker of Oxidative DNA Damage in Acute Exacerbations of COPD: Associations with GOLD Stage and Smoking Status-A Cross Sectional Study.Medicina (Kaunas, Lithuania) · 2026Article
- Proteomic profiling of bronchoalveolar lavage following human segmental endotoxin challenge-a potential exacerbation model.Scientific reports · 2026Article
- Explainable Machine Learning Model Based on Routine Admission Laboratory Tests for Predicting New-Onset Hypoalbuminemia in Hospitalized Older Patients with Acute Exacerbation of COPD.Clinical interventions in aging · 2026Article
- SPG7-Mediated Regulation of mPTP and Mitochondrial Flickering in COPD: A Bioinformatics-Based Prediction of Mechanistic Framework.International journal of chronic obstructive pulmonary disease · 2026Article
- The Role of Tyrosine and C-Reactive Protein in COPD Exacerbations.Journal of clinical medicine · 2025Article
- Cell viability measured by cytotoxicity assay as a biomarker of chronic obstructive pulmonary disease exacerbation: a prospective cohort study.Scientific reports · 2025Article
- Assessing inflammatory protein biomarkers in COPD subjects with and without alpha-1 antitrypsin deficiency.Respiratory research · 2025Article
- Lower Vitamin D During Acute Exacerbation Is Associated with Very Severe Chronic Obstructive Pulmonary Disease.Medicina (Kaunas, Lithuania) · 2025Observational
- Gene Expression Profiles Reveal Distinct Mechanisms Driving Chronic Obstructive Pulmonary Disease Exacerbations.International journal of molecular sciences · 2025Observational
- Article
- Parallel detection of multiple biomarkers in a point-of-care-competent device for the prediction of exacerbations in chronic inflammatory lung disease.Scientific reports · 2024Article
- Water Sorption and Structural Properties of Human Airway Mucus in Health and Muco-Obstructive Diseases.Biomacromolecules · 2024Article
- COPD: systemic proteomic profiles in frequent and infrequent exacerbators.ERJ open research · 2024Article
- Role of circRMRP and circRPL27 in chronic obstructive pulmonary disease.Open life sciences · 2024Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aims of this systematic review were to determine which blood-based molecules have been evaluated as possible biomarkers to diagnose chronic obstructive pulmonary disease (COPD) exacerbations (AECOPD) and to ascertain the quality of these biomarker publications. Patients of interest were those that have been diagnosed with COPD. MEDLINE, EMBASE, and CINAHL databases were searched systematically through February 2015 for publications relating to AECOPD diagnostic biomarkers. We used a modified guideline for the REporting of tumor MARKer Studies (mREMARK) to assess study quality. Additional components of quality included the reporting of findings in a replication cohort and the use of receiver-operating characteristics area-under-the curve statistics in evaluating performance. 59 studies were included, in which the most studied biomarkers were C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). CRP showed consistent elevations in AECOPD compared to control subjects, while IL-6 and TNF-α had variable statistical significance and results. mREMARK scores ranged from 6 to 18 (median score of 13). 12 articles reported ROC analyses and only one study employed a replication cohort to confirm biomarker performance. Studies of AECOPD diagnostic biomarkers remain inconsistent in their reporting, with few studies employing ROC analyses and even fewer demonstrating replication in independent cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.